00:13:29 Vickie Danaher And like we often see prior auths with the other GLP-1 agonists for obesity, we should expect prior auths for orforglipron too
Compare that to the 2.4 mg weekly injection of Wegovy, which delivers far more drug into circulation, and you see why doctors generally consider the injectables more potent for body weight changes
While I questioned Kunin on the growing popularity of these treatments (she says she sees mostly women and a handful of men, some of whom even come in on their lunch breaks), my arm began to feel tingly, as if I had slept on it for too long
Conversely, reports in the health forum were more concentrated, with gastrointestinal disorders, general disorders and administration site conditions, respiratory, thoracic and mediastinal disorders, nervous system disorders, and metabolism and nutrition disorders accounting for 94.03% of the total reports
Adjusting your approach based on early results If you experience strong appetite suppression and steady weight loss during the first month, your dose escalation can proceed on schedule
tirzepatide Liraglutide also mimics only GLP-1 like semaglutide